ArticleAlzheimer's & dementia (Amsterdam, Netherlands)2016
Function and clinical meaningfulness of treatments for mild Alzheimer's disease.
Article in Alzheimer's & dementia (Amsterdam, Netherlands), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Safety, tolerability, immunogenicity, and efficacy of ABvac40 active immunotherapy against Aβ40 in patients with mild cognitive impairment or very mild Alzheimer's disease: A randomized, double-blind, placebo-controlled phase 2 study.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Trial
- Blarcamesine for the treatment of Early Alzheimer's Disease: Results from the ANAVEX2-73-AD-004 Phase IIB/III trial.The journal of prevention of Alzheimer's disease · 2025Trial
- Measuring clinically relevant change in apathy symptoms in ADMET and ADMET 2.International psychogeriatrics · 2024Trial
- Randomized crossover trial of a modified ketogenic diet in Alzheimer's disease.Alzheimer's research & therapy · 2021Trial
- Automatically Calculated Context-Sensitive Features of Connected Speech Improve Prediction of Impairment in Alzheimer's Disease.Journal of speech, language, and hearing research : JSLHR · 2025Article
- Mobility-Based Smartphone Digital Phenotypes for Unobtrusively Capturing Everyday Cognition, Mood, and Community Life-Space in Older Adults: Feasibility, Acceptability, and Preliminary Validity Study.JMIR human factors · 2024Article
- Ketogenic Diet: A Review of Composition Diversity, Mechanism of Action and Clinical Application.Journal of nutrition and metabolism · 2024Review
- Recent Trends in Active and Passive Immunotherapies of Alzheimer's Disease.Antibodies (Basel, Switzerland) · 2023Review
- Review
- Determining the Minimal Important Change of Everyday Functioning in Dementia: Pursuing Clinical Meaningfulness.Neurology · 2022Article
- Meaningful benefits: a framework to assess disease-modifying therapies in preclinical and early Alzheimer's disease.Alzheimer's research & therapy · 2022Review
- Giving meaning to the scores of the Amsterdam instrumental activities of daily living questionnaire: a qualitative study.Health and quality of life outcomes · 2022Article
- Practical recommendations for timely, accurate diagnosis of symptomatic Alzheimer's disease (MCI and dementia) in primary care: a review and synthesis.Journal of internal medicine · 2021Review
- Building clinically relevant outcomes across the Alzheimer's disease spectrum.Alzheimer's & dementia (New York, N. Y.) · 2021Article
- Relationship between Performance on the Mini-Mental State Examination Sub-Items and Activities of Daily Living in Patients with Alzheimer's Disease.Journal of clinical medicine · 2020Article
- The conceptual relevance of assessment measures in patients with mild/mild-moderate Alzheimer's disease.Alzheimer's & dementia (Amsterdam, Netherlands) · 2018Article
- Anti-Aβ single-chain variable fragment antibodies restore memory acquisition in a Drosophila model of Alzheimer's disease.Scientific reports · 2017Article
- Assessing the clinical meaningfulness of slowing CDR-SB progression with disease-modifying therapies for Alzheimer's disease.Alzheimer's & dementia (New York, N. Y.)Article
- Clinically meaningful benefit and real-world evidence in Alzheimer's disease research and care.Alzheimer's & dementia (New York, N. Y.)Article
- Cross-sectional and longitudinal assessments of function in prodromal-to-mild Alzheimer's disease: A comparison of the ADCS-ADL and A-IADL-Q scales.Alzheimer's & dementia (Amsterdam, Netherlands)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionEffectiveness of Alzheimer's disease (AD) treatments is commonly evaluated with coprimary outcomes; cognition with function to ensure clinical meaningfulness of a cognitive effect.
methodsWe reviewed the literature for functional outcomes in mild AD or mild cognitive impairment (MCI) patients (distinct from combined mild-moderate/severe AD) treated with approved AD drugs. Cognitive and functional treatment differences in mild AD patients in solanezumab EXPEDITION/EXPEDITION2 studies were compared across time.
resultsSeven publications provided MCI/mild AD functional outcomes, one of which reported a significant functional treatment effect. Secondary analyses of EXPEDITION studies suggested a smaller functional effect of solanezumab relative to cognition. An increasing effect of solanezumab over 18 months was shown for cognition and function. DISCUSSION: Function as the sole measure to demonstrate clinical meaningfulness of cognitive effects in mild AD may have limitations. For disease-modifying treatments, point differences on cognitive and functional scales should be qualified with duration of treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.